nach oben

Erschienen in:

2022 | OriginalPaper | Buchkapitel

7. Einsatz von Antipsychotika, Antikonvulsiva, Stimulantien, Benzodiazepinen und Hypnotika bei therapieresistenten Depressionen

verfasst von : Stephan Köhler, Cora Schefft

Erschienen in: Therapieresistenz bei Depressionen und bipolaren Störungen

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

Eine Therapieresistenz auf verschiedene pharmakologische und psychotherapeutische Behandlungsoptionen betrifft je nach Studienlage bis zu einem Drittel aller PatientInnen mit einer unipolaren Depression (Fava 2003; Whiteford et al. 2013). Dabei wurden wiederholt therapeutische Optionen jenseits der Behandlung mit Antidepressiva untersucht. In den letzten Jahren gab es zunehmende Evidenz für die Wirksamkeit weiterer Substanzgruppen wie z. B. die atypischen Antipsychotika. Im folgenden Kapitel werden verschiedene Stoffklassen und deren Wirksamkeit in der Behandlung der unipolaren Depression, insbesondere unter Betrachtung der Therapieresistenz besprochen. Ein Schwerpunkt liegt hierbei auf der wissenschaftlichen Evidenz für deren Wirksamkeit bzw. Nichtwirksamkeit sowie auf praktischen Behandlungsempfehlungen für die einzelnen Substanzen. Zusätzlich soll aber auch eine kritische Abwägung hinsichtlich des Risiko-Nutzen-Verhältnisses, insbesondere in Bezug auf potenzielle Nebenwirkungen erfolgen.

Arnt J, Skarsfeldt T (1998) Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18:63–101. https://doi.org/10.1016/S0893-133X(97)00112-7CrossRefPubMed

Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, Moller HJ, World Federation of Societies of Biological Psychiatry. Task Force on Unipolar Depressive D (2013) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry 14:334–385. https://doi.org/10.3109/15622975.2013.804195

Bauer M, Pretorius HW, Constant EL, Earley WR, Szamosi J, Brecher M (2009) Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry 70:540–549. https://doi.org/10.4088/jcp.08m04629CrossRefPubMed

Benasi G, Guidi J, Offidani E, Balon R, Rickels K, Fava GA (2018) Benzodiazepines as a monotherapy in depressive disorders: a systematic review. Psychother Psychosom 87:65–74. https://doi.org/10.1159/000486696CrossRefPubMed

Berman RM, Fava M, Thase ME, Trivedi MH, Swanink R, McQuade RD, Carson WH, Adson D, Taylor L, Hazel J, Marcus RN (2009) Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr 14:197–206. https://doi.org/10.1017/s1092852900020216CrossRefPubMed

Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, Khan A (2007) The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 68:843–853. https://doi.org/10.4088/jcp.v68n0604CrossRefPubMed

Bond DJ, Lam RW, Yatham LN (2010) Divalproex sodium versus placebo in the treatment of acute bipolar depression: a systematic review and meta-analysis. J Affect Disord 124:228–234. S0165-0327(09)00501-1[pii] 10.1016/j.jad.2009.11.008

Bushnell GA, Sturmer T, Gaynes BN, Pate V, Miller M (2017) Simultaneous Antidepressant and Benzodiazepine New Use and Subsequent Long-term Benzodiazepine Use in Adults With Depression, United States, 2001–2014. JAMA Psychiat 74:747–755. https://doi.org/10.1001/jamapsychiatry.2017.1273CrossRef

Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD (1999) A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 60:79–88CrossRefPubMed

Cantu F, Ciappolino V, Enrico P, Moltrasio C, Delvecchio G, Brambilla P (2021) Augmentation with atypical antipsychotics for treatment-resistant depression. J Affect Disord 280:45–53. https://doi.org/10.1016/j.jad.2020.11.006CrossRefPubMed

Chang CM, Sato S, Han C (2013) Evidence for the benefits of nonantipsychotic pharmacological augmentation in the treatment of depression. CNS Drugs 27 Suppl 1:S21-7. https://doi.org/10.1007/s40263-012-0030-1

Corya SA, Williamson D, Sanger TM, Briggs SD, Case M, Tollefson G (2006) A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety 23:364–372. https://doi.org/10.1002/da.20130CrossRefPubMed

Cullen M, Mitchell P, Brodaty H, Boyce P, Parker G, Hickie I, Wilhelm K (1991) Carbamazepine for treatment-resistant melancholia. J Clin Psychiatry 52:472–476PubMed

Davies P, Ijaz S, Williams CJ, Kessler D, Lewis G, and Wiles N (2019) Pharmacological interventions for treatment-resistant depression in adults. Cochrane Database Syst Rev 12:CD010557. https://doi.org/10.1002/14651858.CD010557.pub2

Davis LL, Bartolucci A, Petty F (2005) Divalproex in the treatment of bipolar depression: a placebo-controlled study. J Affect Disord 85:259–266. S0165-0327(04)00371-4[pii] 10.1016/j.jad.2004.09.009

Davis LL, Kabel D, Patel D, Choate AD, Foslien-Nash C, Gurguis GN, Kramer GL, Petty F (1996) Valproate as an antidepressant in major depressive disorder. Psychopharmacol Bull 32:647-52.

DeBattista C, Doghramji K, Menza MA, Rosenthal MH, Fieve RR, Modafinil in Depression Study G (2003) Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. J Clin Psychiatry 64:1057–1064. https://doi.org/10.4088/jcp.v64n0911

DGPPN B, and KBV A. 2015. „für die Leitliniengruppe Unipolare Depression. S3-Leitlinie/Nationale Versor-gungs Leitlinie Unipolare Depression–Langfassung, 2. Auflage. Version 5. 2015.“ In

Dold M, Bartova L, Fugger G, Mitschek MMM, Kautzky A, Frey R, Montgomery S, Zohar J, Mendlewicz J, Souery D, Fabbri C, Serretti A, Kasper S (2020) Add-on benzodiazepine treatment in patients with major depressive disorder – results from a European cross-sectional multicenter study. Eur Neuropsychopharmacol 41:70–80. https://doi.org/10.1016/j.euroneuro.2020.09.636CrossRefPubMed

Dunlop BW, Crits-Christoph P, Evans DL, Hirschowitz J, Solvason HB, Rickels K, Garlow SJ, Gallop RJ, Ninan PT (2007) Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebo-controlled study. J Clin Psychopharmacol 27:614–619. https://doi.org/10.1097/jcp.0b013e31815abefbCrossRefPubMed

Earley WR, Guo H, Nemeth G, Harsanyi J, Thase ME (2018) Cariprazine augmentation to antidepressant therapy in major depressive disorder: results of a randomized, double-blind, placebo-controlled trial. Psychopharmacol Bull 48:62–80PubMedPubMedCentral

Edwards KR, Sackellares JC, Vuong A, Hammer AE, Barrett PS (2001) Lamotrigine Monotherapy Improves Depressive Symptoms in Epilepsy: A Double-Blind Comparison with Valproate. Epilepsy Behav 2:28–36. https://doi.org/10.1006/ebeh.2000.0143CrossRefPubMed

El-Khalili N, Joyce M, Atkinson S, Buynak RJ, Datto C, Lindgren P, Eriksson H (2010) Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol 13:917-32. doi:https://doi.org/10.1017/S1461145710000015

Fava M (2003) Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 53:649–659. https://doi.org/10.1016/s0006-3223(03)00231-2CrossRefPubMed

Fava M, McCall WV, Krystal A, Wessel T, Rubens R, Caron J, Amato D, Roth T (2006) Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry 59:1052–1060. https://doi.org/10.1016/j.biopsych.2006.01.016CrossRefPubMed

Fava M, Mischoulon D, Iosifescu D, Witte J, Pencina M, Flynn M, Harper L, Levy M, Rickels K, Pollack M (2012) A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study). Psychother Psychosom 81:87–97. https://doi.org/10.1159/000332050CrossRefPubMed

Fava M, Thase ME, DeBattista C (2005) A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J Clin Psychiatry 66:85–93. https://doi.org/10.4088/jcp.v66n0112CrossRefPubMed

Furukawa TA, Streiner DL, and Young LT (2002) Antidepressant and benzodiazepine for major depression. Cochrane Database Syst Rev:CD001026. doi:https://doi.org/10.1002/14651858.CD001026

Geddes JR, Calabrese JR, Goodwin GM (2009) Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry 194:4–9. 194/1/4[pii] https://doi.org/10.1192/bjp.bp.107.048504

Ghaemi SN, Gilmer WS, Goldberg JF, Zablotsky B, Kemp DE, Kelley ME, Bauer AD, Fleck J, Filkowski MM, Stan VA, Dunn RT (2007) Divalproex in the treatment of acute bipolar depression: a preliminary double-blind, randomized, placebo-controlled pilot study. J Clin Psychiatry 68:1840–1844CrossRefPubMed

Goh KK, Chen CH, Chiu YH, Lu ML (2019) Lamotrigine augmentation in treatment-resistant unipolar depression: a comprehensive meta-analysis of efficacy and safety. J Psychopharmacol 33:700–713. https://doi.org/10.1177/0269881119844199CrossRefPubMed

Goss AJ, Kaser M, Costafreda SG, Sahakian BJ, Fu CH (2013) Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials. J Clin Psychiatry 74:1101–1107. https://doi.org/10.4088/JCP.13r08560CrossRefPubMed

Health NCCfM (2010) „Depression: the treatment and management of depression in adults (updated edition).“ In.: British Psychological Society.

Jon DI, Kim DH, Seo HJ, Kwon YJ, Kim MD, Yang JC, Suh HS, Min KJ, Pae CU, Bahk WM (2013) Augmentation of aripiprazole for depressed patients with an inadequate response to antidepressant treatment: a 6-week prospective, open-label, multicenter study. Clin Neuropharmacol 36:157–161. DOI: 10.1097/WNF.0b013e3182a31f3dCrossRefPubMed

Keitner GI, Garlow SJ, Ryan CE, Ninan PT, Solomon DA, Nemeroff CB, Keller MB (2009) A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. J Psychiatr Res 43:205–214. https://doi.org/10.1016/j.jpsychires.2008.05.003CrossRefPubMed

Kishi T, Matsunaga S, Iwata N (2017) Efficacy and tolerability of Z-drug adjunction to antidepressant treatment for major depressive disorder: a systematic review and meta-analysis of randomized controlled trials. Eur Arch Psychiatry Clin Neurosci 267:149–161. https://doi.org/10.1007/s00406-016-0706-5CrossRefPubMed

Kleeblatt J, Betzler F, Kilarski LL, Bschor T, Kohler S (2017) Efficacy of off-label augmentation in unipolar depression: a systematic review of the evidence. Eur Neuropsychopharmacol 27:423–441. https://doi.org/10.1016/j.euroneuro.2017.03.003CrossRefPubMed

Lavretsky H, Park S, Siddarth P, Kumar A, Reynolds CF 3rd (2006) Methylphenidate-enhanced antidepressant response to citalopram in the elderly: a double-blind, placebo-controlled pilot trial. Am J Geriatr Psychiatry 14:181–185. https://doi.org/10.1097/01.JGP.0000192503.10692.9fCrossRefPubMed

Li X, Xing B, Yu E, Chen W, Wu H (2013) The combined treatment of venlafaxine and quetiapine for treatment-resistant depression: a clinical study. J Neuropsychiatry Clin Neurosci 25:157–160. https://doi.org/10.1176/appi.neuropsych.12070171CrossRefPubMed

Macritchie K, Geddes JR, Scott J, Haslam D, de Lima M, and Goodwin G (2003) Valproate for acute mood episodes in bipolar disorder. Cochrane Database Syst Rev:CD004052. https://doi.org/10.1002/14651858.CD004052

Mahmoud RA, Pandina GJ, Turkoz I, Kosik-Gonzalez C, Canuso CM, Kujawa MJ, and Gharabawi-Garibaldi GM (2007) Risperidone for treatment-refractory major depressive disorder: a randomized trial. Ann Intern Med 147:593–602. https://doi.org/10.7326/0003-4819-147-9-200711060-00003

Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, Trivedi MH, Thase ME, Berman RM (2008) The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 28:156–165. https://doi.org/10.1097/JCP.0b013e31816774f9CrossRefPubMed

Nelson JC, Papakostas GI (2009) Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 166:980–991. https://doi.org/10.1176/appi.ajp.2009.09030312CrossRefPubMed

Ogawa Y, Takeshima N, Hayasaka Y, Tajika A, Watanabe N, Streiner D, Furukawa TA (2019) Antidepressants plus benzodiazepines for adults with major depression. Cochrane Database Syst Rev 6:CD001026. https://doi.org/10.1002/14651858.CD001026.pub2

Otani K, Yasui N, Kaneko S, Ohkubo T, Osanai T, Sugawara K (1996) Carbamazepine augmentation therapy in three patients with trazodone-resistant unipolar depression. Int Clin Psychopharmacol 11:55–57. https://doi.org/10.1097/00004850-199603000-00008CrossRefPubMed

Patkar AA, Masand PS, Pae CU, Peindl K, Hooper-Wood C, Mannelli P, Ciccone P (2006) A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. J Clin Psychopharmacol 26:653–656. https://doi.org/10.1097/01.jcp.0000246212.03530.fdCrossRefPubMed

Post RM, Uhde TW, Roy-Byrne PP, Joffe RT (1986) Antidepressant effects of carbamazepine. Am J Psychiatry 143:29–34. https://doi.org/10.1176/ajp.143.1.29CrossRefPubMed

Rapaport MH, Gharabawi GM, Canuso CM, Mahmoud RA, Keller MB, Bossie CA, Turkoz I, Lasser RA, Loescher A, Bouhours P, Dunbar F, Nemeroff CB (2006) Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology 31:2505–2513. https://doi.org/10.1038/sj.npp.1301113CrossRefPubMed

Ravindran AV, Kennedy SH, O’Donovan MC, Fallu A, Camacho F, Binder CE (2008) Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry 69:87–94. https://doi.org/10.4088/jcp.v69n0112CrossRefPubMed

Richelson E, Souder T (2000) Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 68:29–39. https://doi.org/10.1016/s0024-3205(00)00911-5CrossRefPubMed

Rybakowski JK, Suwalska A, and Chlopocka-Wozniak M (1999) Potentiation of antidepressants with lithium or carbamazepine in treatment-resistant depression. Neuropsychobiology 40:134-9. https://doi.org/10.1159/000026610

Schifano F, Chiappini S, Corkery JM, Guirguis A (2019) An insight into z-drug abuse and dependence: an examination of reports to the european medicines agency database of suspected adverse drug reactions. Int J Neuropsychopharmacol 22:270–277. https://doi.org/10.1093/ijnp/pyz007CrossRefPubMedPubMedCentral

Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, Roth BL, Mailman R (2003) Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28:1400–1411. https://doi.org/10.1038/sj.npp.1300203CrossRefPubMed

Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, Buras WR, Bymaster FP, Zhang W, Spencer KA, Feldman PD, Meltzer HY (2001) A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 158:131–134. https://doi.org/10.1176/appi.ajp.158.1.131CrossRefPubMed

Smith LA, Cornelius VR, Azorin JM, Perugi G, Vieta E, Young AH, Bowden CL (2010) Valproate for the treatment of acute bipolar depression: systematic review and meta-analysis. J Affect Disord 122:1–9. S0165-0327(09)00495-9[pii] 10.1016/j.jad.2009.10.033

Spielmans GI, Berman MI, Linardatos E, Rosenlicht NZ, Perry A, Tsai AC (2013) Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS Med 10:e1001403. https://doi.org/10.1371/journal.pmed.1001403CrossRefPubMedPubMedCentral

Svestka J, Rysanek R, Ceskova E (1991) Treatment of endogenous depressions with valpromide (open study). Homeost Health Dis 33:291–292PubMed

Thase ME, Youakim JM, Skuban A, Hobart M, Zhang P, McQuade RD, Nyilas M, Carson WH, Sanchez R, Eriksson H (2015) Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study. J Clin Psychiatry 76:1232–1240. https://doi.org/10.4088/JCP.14m09689CrossRefPubMed

Vazquez GH, Bahji A, Undurraga J, Tondo L, Baldessarini RJ (2021) Efficacy and tolerability of combination treatments for major depression: antidepressants plus second-generation antipsychotics vs. esketamine vs. lithium. J Psychopharmacol 35:890–900. https://doi.org/10.1177/02698811211013579CrossRefPubMed

Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, Charlson FJ, Norman RE, Flaxman AD, Johns N, Burstein R, Murray CJ, Vos T (2013) Global burden of disease attributable to mental and substance use disorders: findings from the global burden of disease study 2010. Lancet 382:1575–1586. https://doi.org/10.1016/S0140-6736(13)61611-6

Zhang ZJ, Kang WH, Tan QR, Li Q, Gao CG, Zhang FG, Wang HH, Ma XC, Chen C, Wang W, Guo L, Zhang YH, Yang XB, Yang GD (2007) Adjunctive herbal medicine with carbamazepine for bipolar disorders: a double-blind, randomized, placebo-controlled study. J Psychiatr Res 41:360–369. S0022-3956(05)00079-8[pii] https://doi.org/10.1016/j.jpsychires.2005.06.002

Zhou X, Ravindran AV, Qin B, Del Giovane C, Li Q, Bauer M, Liu Y, Fang Y, da Silva T, Zhang Y, Fang L, Wang X, Xie P (2015) Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis. J Clin Psychiatry 76:e487–e498. https://doi.org/10.4088/JCP.14r09204

Titel: Einsatz von Antipsychotika, Antikonvulsiva, Stimulantien, Benzodiazepinen und Hypnotika bei therapieresistenten Depressionen
verfasst von: Stephan Köhler
Cora Schefft
Verlag: Springer Berlin Heidelberg
Buch: Therapieresistenz bei Depressionen und bipolaren Störungen
Print ISBN: 978-3-662-65733-1

Electronic ISBN: 978-3-662-65734-8

Copyright-Jahr: 2022
DOI: https://doi.org/10.1007/978-3-662-65734-8_7

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

7. Einsatz von Antipsychotika, Antikonvulsiva, Stimulantien, Benzodiazepinen und Hypnotika bei therapieresistenten Depressionen

Zusammenfassung

Neu im Fachgebiet Psychiatrie

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

So wirken verschiedene Alkoholika auf den Blutdruck

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

ADHS-Medikation erhöht das kardiovaskuläre Risiko

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Neu im Fachgebiet Psychiatrie

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

So wirken verschiedene Alkoholika auf den Blutdruck

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

ADHS-Medikation erhöht das kardiovaskuläre Risiko